Clinical trials
Hypersensitivity trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 7 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
| Unknown status | 7 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Terminated | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aerovance, Inc. | 5 |
| Aimmune Therapeutics, Inc. | 5 |
| Imperial College London | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Novartis Pharmaceuticals | 3 |
| University of Nottingham | 3 |
| AstraZeneca | 2 |
| Celgene | 2 |
| Cogent Biosciences, Inc. | 2 |
| Joel Puente | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypersensitivity | 70 |
| Asthma | 17 |
| Peanut Hypersensitivity | 9 |
| Food Hypersensitivity | 7 |
| Immune System Diseases | 6 |
| Rhinitis, Allergic | 6 |
| Infections | 5 |
| Eczema | 4 |
| Fatigue | 4 |
| Hypersensitivity, Immediate | 4 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.